Newleos doses the first participant in a Phase 1b study of NTX-2001, a potential first-in-class TAAR1 partial agonist for ...

CREATE Medicines, Inc., ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today ...

Nana Ama, a First Class graduate from the University of Ghana, now runs a successful consultancy business in China, aiding ...

First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal TrialClinical site activation and patient enrollment expected to commence later this yearLarge unmet clinical need for approximately 3 ...

Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer CenterData ...

Fractyl Health announced a first-in-human trial for RJVA-001, targeting T2D and obesity, pending regulatory approval by 2026. Fractyl Health, Inc. has announced the submission of the first module of ...

High Impact Session presented at Heart Rhythm Society's Congress in ChicagoFirst time showing results of new Less Invasive ...